News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel
Sign In

Noted Pathologist George Lundberg, M.D., Sees Opportunity for Pathology Profession to be Leaders in Diagnostics during the Era of Genomics

Noted pathologist encourages pathology profession to step up and assert leadership in clinical diagnostics as it enters the era of genomics-based medicine

Pathologists, embrace molecular testing or become irrelevant. In essence, that’s the message from pathology maven George D. Lundberg, M.D..

Lundberg is well known to pathologists in America. A board-certified pathologist himself, Lundberg served 17 years as Editor in Chief of the Journal of the American Medical Association (JAMA). He continues to write and blog for a variety of healthcare publications and Web sites.

That means Lundberg has watched the evolution of medicine from a unique perspective for an extended period of time. The fact that he recently issued a clear and unambiguous call to action for the pathology profession means that pathologists  and clinical laboratory managers should take heed. (more…)

Weill Cornell and New York Presbyterian to Create New Precision Medicine Institute to Use Genome Sequencing to Individualize Cancer Treatment

Pathologist Mark Rubin, M.D., is named to direct this early effort to adapt diagnostic and gene sequencing technologies to support personalized medicine

Following several years of experience with whole genome sequencing of tumors, two premier medical institutions announced their intent to move to the next step and establish an institute to support precision medicine. A prominent pathologist was named to head up this new institute.

Weill Cornell Medical College and New York-Presbyterian Hospital established a new, cutting-edge translational medicine research facility. It is called the Precision Medicine Institute and will use patients’ unique genetic profiles to develop individualized approaches for treating prostate cancer. (more…)

Tiny Faroe Islands to Begin Sequencing Genomes of All 50,000 Residents in Ambitious Effort to Advance Personalized Medicine

Because of isolation from the worldwide DNA pool for the past 1,200 years, Faroese population is vulnerable to recessive gene disorders

Because of the dramatic—and still falling—cost of DNA sequencing, an ambitious project is launching with the goal of sequencing the full DNA of all 50,000 residents of the Faroe Islands. When completed, this project has the potential to reshape molecular diagnostics and clinical laboratory testing.

FarGen is the name of this effort and pathologists and clinical laboratory managers will want to follow its progress. Organizers of this unique effort expect that it will speed up the use of personalized medicine in mainstream medicine. This tiny, self-governing Danish land, located between Iceland and Norway, is moving forward with plans to decipher complete DNA sequences for every one of its 50,000 citizens. (more…)

Geneticists Question Balance of Media Coverage of the Value of Gene Sequencing and Personalized Medicine

Pathologists and medical laboratory managers will want to stay informed about how genome sequencing data is being translated into clinical applications

There is a vigorous debate unfolding about the ability of personal genome sequencing to reliably predict disease. That is not news to pathologists and clinical laboratory managers. What is a novel twist in the arguments by both sides is whether media coverage has the potential to undermine public support for genomics and personalized medicine.

For example, one media story on a study of the power of personal genome sequencing to predict disease drew fire from some genomics experts on two counts. First, they questioned the validity of the study. Second, they fear that such coverage by the media could weaken public support for genomics and personalized medicine.

Public Perception of the Value of Genetic Testing

During 2012, The New York Times published a story on a study by Johns Hopkins University that sought to determine whether genetic testing can predict future disease. According to the results of this particular study, it cannot.

Some noted genomics experts took the Times—and the study—to task. One is Ronald W. Davis, Ph.D., Professor of Biochemistry and Genetics at Stanford University School of Medicine. Davis is Director of the Stanford Genome Technology Center. (more…)

Whole Gene Sequencing for Diagnosis Is Goal of Beth Israel Deaconess Medical Center and GenomeQuest in a New Collaboration

Goals are to use whole gene sequencing to develop better clinical laboratory assays in support of personalized medicine

Creating new clinical laboratory tests to support personalized medicine is one goal of a unique collaboration recently announced that involves the pathology department at Beth Israel Deaconess Medical Center (BIDMC) and GenomeQuest, Inc. (NASDAQ:GQ). The two collaborators are expanding a relationship launched several years ago that involved doing whole genome sequencing of tumors.

More specifically, the expanded relationship will be a two-year collaboration to develop whole-genome analysis (WGA) applications for personalized medicine. The move signals pathologists and clinical laboratory managers that first movers are taking steps to address the growing need for clinical genomics informatics infrastructure.

“The plummeting cost of sequencing and the increasing volume of predictive, public studies makes the clinical application of genomics not just a practicality but a healthcare imperative,” declared GenomeQuest CEO Richard Resnick. “We believe that our collaboration with a combined innovation and delivery leader like BIDMC is a major step forward in expanding genomics and its rewards from the bench to the bedside.” (more…)

;